STROKOG (stroke and cognition consortium): An international conso.pdf (205.03 kB)
0/0

STROKOG (stroke and cognition consortium): An international consortium to examine the epidemiology, diagnosis, and treatment of neurocognitive disorders in relation to cerebrovascular disease.

Download (205.03 kB)
journal contribution
posted on 22.11.2019 by Perminder S. Sachdev, Jessica W. Lo, John D. Crawford, Lisa Mellon, Anne Hickey, David Williams, Régis Bordet, Anne-Marie Mendyk, Patrick Gelé, Dominique Deplanque, Hee-Joon Bae, Jae-Sung Lim, Amy Brodtmann, Emilio Werden, Toby Cumming, Sebastian Köhler, Frans RJ Verhey, Yan-Hong Dong, Hui Hui Tan, Christopher Chen, Xu Xin, Raj N. Kalaria, Louise M. Allan, Rufus O. Akinyemi, Adesola Ogunniyi, Aleksandra Klimkowicz-Mrowiec, Martin Dichgans, Frank A. Wollenweber, Vera Zietemann, Michael Hoffmann, David W. Desmond, Thomas Linden, Christian Blomstrand, Björn Fagerberg, Ingmar Skoog, Olivier Godefroy, Mélanie Barbay, Martine Roussel, Byung-Chul Lee, Kyung-Ho Yu, Joanna Wardlaw, Stephen J. Makin, Fergus N. Doubal, Francesca M. Chappell, Velandai K. Srikanth, Amanda G. Thrift, Geoffrey A. Donnan, Nagaendran Kandiah, Russell J. Chander, Xuling Lin, Charlotte Cordonnier, Solene Moulin, Costanza Rossi, Behnam Sabayan, David J. Stott, J Wouter Jukema, Susanna Melkas, Hanna Jokinen, Timo Erkinjuntti, Vincent CT Mok, Adrian Wong, Bonnie YK Lam, Didier Leys, Hilde Hénon, Stéphanie Bombois, Darren M. Lipnicki, Nicole A. Kochan, STROKOG

INTRODUCTION: The Stroke and Cognition consortium (STROKOG) aims to facilitate a better understanding of the determinants of vascular contributions to cognitive disorders and help improve the diagnosis and treatment of vascular cognitive disorders (VCD).

METHODS: Longitudinal studies with ≥75 participants who had suffered or were at risk of stroke or TIA and which evaluated cognitive function were invited to join STROKOG. The consortium will facilitate projects investigating rates and patterns of cognitive decline, risk factors for VCD, and biomarkers of vascular dementia.

RESULTS: Currently, STROKOG includes 25 (21 published) studies, with 12,092 participants from five continents. The duration of follow-up ranges from 3 months to 21 years.

DISCUSSION: Although data harmonization will be a key challenge, STROKOG is in a unique position to reuse and combine international cohort data and fully explore patient level characteristics and outcomes. STROKOG could potentially transform our understanding of VCD and have a worldwide impact on promoting better vascular cognitive outcomes.

Funding

STROKOG: The Dementia Momentum fund from the Centre of Healthy Brain Ageing (CHeBA), UNSW Medicine, University of New South Wales and Vincent Fairfax Family Foundation. ASPIRE-S: Irish Health Research Board (HRB; grant number 1404/7400). CASPER and CODAS: Maastricht University, Health Foundation Limburg, and the Adriana van Rinsum-Ponsen Stichting. COAST: National Medical Research Council (NMRC/CG/NUHS/2010) and National University Health System National Clinician Scientist Program (NUHS NCSP). CogFAST-UK: Newcastle Centre for Brain Ageing and Vitality (BBSRC, EPSRC, ESRC and MRC, LLHW; G0700718). The original CogFAST-UK research programmes were supported by the UK Medical Research Council (MRC, G0500247 and G9817621). CogFAST-Nigeria: R.O.A. was supported by a fellowship from the International Brain Research Organization (IBRO) Paris, France and by an ORS Award from the Newcastle University, UK. DEDEMAS: Vascular Dementia Research Foundation. Flutemetamol (18F) was provided by GE Healthcare. Epi USA: National Institutes of Health (grants R01-NS26179 and P01-AG07232). GRECOG-VASC: French Health Ministry. MSS-II: Wellcome Trust number WT088134/Z/09/A.Row Fogo Trust. NEMESIS: NHMRC, Victorian Health Promotion Foundation, Austin Hospital Medical Research Foundation, Perpetual Trustees, National Stroke Foundation, Foundation for High Blood Pressure Research. NNI: National Neuroscience Institute, Singapore. PROSPER: The original PROSPER clinical trial was founded by an investigator initiated grant from Bristol-Myers Squibb, USA. SAM: Helsinki University Central Hospital, Helsinki. STRIDE: Health and Health Services Research Fund (0708041) of the Food and Health Bureau of the Government of the HKSAR, the Lui Che Woo Institute of Innovative Medicine, and Therese Pei Fong Chow Research Centre for Prevention of Dementia. SSS: National Health and Medical Research Council.

History

Comments

The original article is available at www.sciencedirect.com

Published Citation

Sachdev PS, Lo JW, Crawford JD, Mellon L, Hickey A, Williams D, Bordet R, Mendyk AM, Gelé P, Deplanque D, Bae HJ, Lim JS, Brodtmann A, Werden E, Cumming T, Köhler S, Verhey FR, Dong YH, Tan HH, Chen C, Xin X, Kalaria RN, Allan LM, Akinyemi RO Ogunniyi A, Klimkowicz-Mrowiec A, Dichgans M, Wollenweber FA, Zietemann V, Hoffmann M, Desmond DW, Linden T, Blomstrand C, Fagerberg B, Skoog I, Godefroy O, Barbay M, Roussel M, Lee BC, Yu KH, Wardlaw J, Makin SJ, Doubal FN, Chappell FM, Srikanth VK, Thrift AG, Donnan GA, Kandiah N, Chander RJ, Lin X, Cordonnier C, Moulin S, Rossi C, Sabayan B, Stott DJ, Jukema JW, Melkas S, Jokinen H, Erkinjuntti T, Mok VC, Wong A, Lam BY, Leys D, Hénon H, Bombois S, Lipnicki DM, Kochan NA; STROKOG. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2016;7:11-23.

Publication Date

01/01/2017

Publisher

Elsevier

PubMed ID

28138511

Exports